Conferences - Results from #9620

ASCO 2017: Next-generation sequencing of tissue and cell free DNA (cfDNA) to identify somatic and germline alterations in advanced prostate cancer June 5, 2017

ASCO 2017: A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209 June 5, 2017

ASCO 2017: The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials June 5, 2017

ASCO 2017: Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients June 5, 2017

ASCO 2017: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT) June 5, 2017

ASCO 2017: Can Subgroup Analyses Identify Enrichment Strategies for Adjuvant RCC Studies? June 5, 2017

ASCO 2017: The clinical role of purified protein derivative skin test reaction in patients with non-muscle invasive bladder cancer treated with bacillus-Calmette Guerin June 5, 2017

ASCO 2017: Cabazitaxel in patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy: Results of a phase II trial—CAB-B1. June 5, 2017

ASCO 2017: Effectiveness of the Moreau strain of Bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer June 5, 2017

ASCO 2017: Survival outcomes in elderly patients with muscle invasive bladder cancer: An analysis of the National Cancer Database June 5, 2017

ASCO 2017: Emerging VEGF-I/O Combinations: Efficacy and Toxicity June 5, 2017

ASCO 2017: Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas June 5, 2017

ASCO 2017: Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037 June 5, 2017

ASCO 2017: Bladder Cancer: 'Novel' Becomes the Norm June 5, 2017

ASCO 2017: Intra-patient heterogeneity in urothelial cancer circulating tumor cells and PDL1 expression to identify biomarkers of response and new therapeutic targets June 5, 2017

ASCO 2017: Comparison of somatic mutation profiles from cell free DNA versus tissue in metastatic urothelial carcinoma June 5, 2017

ASCO 2017: A phase I/II study to assess the safety and efficacy of pazopanib and pembrolizumab in patients with advanced renal cell carcinoma June 5, 2017

ASCO 2017: Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer June 5, 2017

ASCO 2017: Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab in cisplatin-ineligible advanced urothelial cancer June 5, 2017

ASCO 2017: Need for re-evaluation of current guidelines based on results from germline genetic testing in prostate cancer June 5, 2017

Page 482 of 616